Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Oncolytic virotherapy (OV) is an emerging class of immunotherapeutic drugs. Their mechanism of action is two-fold: direct cell lysis and unmasking of the cancer through immunogenic cell death, which allows the immune system to recognize and eradicate tumours. Breast cancer is the most common cancer in women and is challenging to treat with immunotherapy modalities because it is classically an immunogenically “cold” tumour type. This provides an attractive niche for OV, given viruses have been shown to turn “cold” tumours “hot,” thereby opening a plethora of treatment opportunities. There has been a number of pre-clinical attempts to explore the use of OV in breast cancer; however, these have not led to any meaningful clinical trials. This review considers both the potential and the barriers to OV in breast cancer, namely, the limitations of monotherapy and the scope for combination therapy, improving viral delivery and challenges specific to the breast cancer population (e.g., tumour subtype, menopausal status, age).
Funding Information
  • Sheffield Teaching Hospitals Charity (12053)
  • Team Verrico (MS/149394)
  • Cancer Research UK (C25574/A24321)
  • European Union’s Horizon 2020 research and innovation programme under the Marie Skcodowska-Curie grant (PRISAR2)

This publication has 78 references indexed in Scilit: